TRIM14 inhibits hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A protein

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Shanshan ^a,b,f   Chen, Yongzhi ^c,d   Li, Chunfeng ^b,f   Wu, Yaoxing ^a   Guo, Lei ^a   Peng, Changwei ^a   Huang, Yueping ^a   Cheng, Genhong ^b,c,e,f   Qin, F Xiao Feng ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c INSTITUTE OF BIOPHYSICS   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SUZHOU INSTITUTE OF SYSTEMS MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; NS-5 PROTEIN, HEPATITIS C VIRUS; TRIM14 PROTEIN, HUMAN; VIRAL PROTEIN;

CHEMISTRY; GENE KNOCKOUT; GENETICS; HEPACIVIRUS; HEPATITIS C; HOST PATHOGEN INTERACTION; HUMAN; LIVER CELL; PATHOGENICITY; PROTEIN DEGRADATION; PRY-SPRY DOMAIN; UBIQUITINATION; VIROLOGY;

B30.2-SPRY DOMAIN; CARRIER PROTEINS; GENE KNOCKOUT TECHNIQUES; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEOLYSIS; UBIQUITINATION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84984941796     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32336     Document Type: Article

References (46)

1. Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
2. Bartenschlager, R., Penin, F., Lohmann, V. & Andre, P. Assembly of infectious hepatitis C virus particles. Trends Microbiol 19, 95-103, doi: 10.1016/j.tim.2010.11.005 (2011).
3. Moriishi, K. & Matsuura, Y. Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol 3, 54, doi: 10.3389/fmicb.2012.00054 (2012).
4. Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333-1342, doi: 10.1002/hep.26141 (2013).
5. Mitchell, A. M. et al. Transmitted/founder hepatitis C viruses induce cell-type- and genotype-specific differences in innate signaling within the liver. MBio 6(2), p. e02510. (2015).
6. Rosen, H. R. et al. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 123, 4121-4130 (2013).
7. Murray, C. L. & Rice, C. M. Hepatitis C: An unsuspected drug target. Nature 465, 42-44, doi: 10.1038/465042a (2010).
8. Bartenschlager, R., Lohmann, V. & Penin, F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 11, 482-496, doi: 10.1038/nrmicro3046 (2013).
9. Kohler, J. J. et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist 7, 41-56, doi: 10.2147/IDR. S36247 (2014).
10. Tellinghuisen, T. L., Marcotrigiano, J. & Rice, C. M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435, 374-379, doi: 10.1038/nature03580 (2005).
11. Lim, P. J. et al. Correlation between NS5A dimerization and hepatitis C virus replication. J Biol Chem 287, 30861-30873, doi: 10.1074/jbc.M112.376822 (2012).
12. Ansari, I. U. & Striker, R. Subtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virus. Viruses 4, 3303-3315 (2012).
13. Hwang, J. et al. Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol 84, 12480-12491, doi: 10.1128/JVI.01319-10 (2010).
14. Romero, B. I. et al. NS5A Domain 1 and Polyprotein Cleavage Kinetics Are Critical for Induction of Double-Membrane Vesicles Associated with Hepatitis C Virus Replication. MBio 6(4), p e00759 (2015).
15. Hiet M. S. et al. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. J Hepatol 63(4), 829-837 (2015).
16. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801, doi: 10.1016/j.cell.2006.02.015 (2006).
17. Lee, M. S. & Kim, Y. J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 76, 447-480, doi: 10.1146/annurev.biochem.76.060605.122847 (2007).
18. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820, doi: 10.1016/j.cell.2010.01.022 (2010).
19. Wang, Y. et al. TRIM35 negatively regulates TLR7- and TLR9-mediated type I interferon production by targeting IRF7. FEBS Lett 589, 1322-1330, doi: 10.1016/j.febslet.2015.04.019 (2015).
20. Liu, S. Y., Sanchez, D. J. & Cheng, G. New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol 23, 57-64, doi: 10.1016/j.coi.2010.11.003 (2011).
21. Chen, Y. et al. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci Rep 4, 7242, doi: 10.1038/srep07242 (2014).
22. Yan, J., Li, Q., Mao, A. P., Hu, M. M. & Shu, H. B. TRIM4 modulates type I interferon induction and cellular antiviral response by targeting RIG-I for K63-linked ubiquitination. J Mol Cell Biol 6, 154-163, doi: 10.1093/jmcb/mju005 (2014).
23. Nisole, S., Stoye, J. P. & Saib, A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3, 799-808, doi: 10.1038/nrmicro1248 (2005).
24. Taylor, R. T. et al. TRIM79alpha, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host Microbe 10, 185-196, doi: 10.1016/j.chom.2011.08.004 (2011).
25. Towers, G. J. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4, 40, doi: 10.1186/1742-4690-4-40 (2007).
26. Zhang, S., Guo, J. T., Wu, J. Z. & Yang, G. Identification and characterization of multiple TRIM proteins that inhibit hepatitis B virus transcription. PLoS One 8, e70001, doi: 10.1371/journal.pone.0070001 (2013).
27. Uchil, P. D., Quinlan, B. D., Chan, W. T., Luna, J. M. & Mothes, W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4, e16, doi: 10.1371/journal.ppat.0040016 (2008).
28. Bjorndal, A. S., Szekely, L. & Elgh, F. Ebola virus infection inversely correlates with the overall expression levels of promyelocytic leukaemia (PML) protein in cultured cells. BMC Microbiol 3, 6 (2003).
29. Perfettini, J. L. et al. The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope. Cell Death Differ 16, 298-311, doi: 10.1038/cdd.2008.158 (2009).
30. Turrini, F., Di Pietro, A. & Vicenzi, E. Lentiviral Effector Pathways of TRIM Proteins. DNA Cell Biol 33, 191-197, doi: 10.1089/dna.2014.2374 (2014).
31. Bouazzaoui, A. et al. Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages. Virology 356, 79-94, doi: 10.1016/j.virol.2006.07.025 (2006).
32. Kajaste-Rudnitski, A. et al. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NFkappaB-responsive long terminal repeat elements. J Virol 85, 5183-5196, doi: 10.1128/JVI.02302-10 (2011).
33. Barr, S. D., Smiley, J. R. & Bushman, F. D. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 4, e1000007, doi: 10.1371/journal.ppat.1000007 (2008).
34. Di Pietro, A. et al. TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol 87, 4523-4533, doi: 10.1128/JVI.02548-12 (2013).
35. Yang, C. et al. Interferon alpha (IFNalpha)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. Cell Mol Immunol 13, 94-102, doi: 10.1038/cmi.2014.131 (2016).
36. Eldin, P. et al. TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. J Gen Virol 90, 536-545, doi: 10.1099/vir.0.006288-0 (2009).
37. Gao, B., Duan, Z., Xu, W. & Xiong, S. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50, 424-433, doi: 10.1002/hep.23011 (2009).
38. Zhou, Z. et al. TRIM14 is a mitochondrial adaptor that facilitates retinoic acid-inducible gene-I-like receptor-mediated innate immune response. Proc Natl Acad Sci USA 111, E245-254, doi: 10.1073/pnas.1316941111 (2014).
39. Su, X. et al. Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NF-kB signaling pathway. Oncotarget, doi: 10.18632/oncotarget.6941 (2016).
40. Reymond A. et al. The tripartite motif family identifies cell compartments. EMBO. doi: 10.1093/emboj/20.9.2140 (2001).
41. Massiah, M. A. et al. Solution structure of the MID1 B-box2 CHC(D/C)C(2)H(2) zinc-binding domain: insights into an evolutionarily conserved RING fold. JMol Bioi. doi: 10.1016/j.jmb.2007.03.017 (2007).
42. Metz, P. et al. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 56, 2082-2093, doi: 10.1002/hep.25908 (2012).
43. Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481-485, doi: 10.1038/nature09907 (2011).
44. Kimsa, M. W. et al. Differential expression of tripartite motif-containing family in normal human dermal fibroblasts in response to porcine endogenous retrovirus infection. Folia Biol (Praha) 60, 144-151 (2014).
45. Nenasheva, V. V. et al. Enhanced expression of trim14 gene suppressed Sindbis virus reproduction and modulated the transcription of a large number of genes of innate immunity. Immunol Res 62, 255-262, doi: 10.1007/s12026-015-8653-1 (2015).
46. Yang, Z. et al. USP18 negatively regulates NF-kappaB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms. Scientific reports 5, 12738, doi: 10.1038/srep12738 (2015).